Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5,169,697
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
9,845,770
-
Shares change
-
-4,986,013
-
Total reported value, excl. options
-
$101,108,715
-
Value change
-
-$50,175,043
-
Number of buys
-
16
-
Number of sells
-
-35
-
Price
-
$10.27
Significant Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q4 2022
74 filings reported holding CERO - CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share as of Q4 2022.
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,845,770 shares
.
Largest 10 shareholders include Saba Capital Management, L.P. (1,212,426 shares), HSBC HOLDINGS PLC (729,499 shares), JANUS HENDERSON GROUP PLC (650,000 shares), Westchester Capital Management, LLC (611,264 shares), Polar Asset Management Partners Inc. (599,999 shares), Periscope Capital Inc. (549,359 shares), Beryl Capital Management LLC (542,376 shares), HGC Investment Management Inc. (500,000 shares), First Trust Capital Management L.P. (426,692 shares), and BERKLEY W R CORP (384,630 shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.